Humanized immunoglobulin reactive with α4β7 integrin
US7147851B1 · kind B1 · utility
47Cited by
21References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 15, 1996 |
| Grant date | Dec 12, 2006 |
| Priority date | — |
| Expiry date | Jul 24, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to humanized immunoglobulins having binding specificity for α4β7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region). In one embodiment, the humanized immunoglobulin can compete with murine Act-1 for binding to human α4β7 integrin. In a preferred embodiment, the antigen binding region of the humanized immunoglobulin comprises each of the complementarity determining regions of the light and heavy chains of the murine Act-1 antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.